Transaction #8369 · Form 4 · 0001231919-25-000499
Wave Life Sciences, Inc. · Purchase · Ordinary Shares
Wave Life Sciences, Inc. · Transacted November 13, 2025 · Filed November 14, 2025
What does this filing report?
An SEC Form 4 filing for Wave Life Sciences, Inc. records a purchase involving Ordinary Shares on November 13, 2025. The reported quantity was 1,000. The filing date is November 14, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Wave Life Sciences, Inc.
- Company CIK
- 0001631574
- Security type
- Non-derivative
- Acquisition type
- Purchase · Code P
- Quantity acquired
- 1,000
- Reported price
- 6.6875 · See footnotes
- Reference value
- 6,687.5
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 18,203,009
- Ownership description
- See footnotes
- SEC acceptance time
- Nov 14, 2025, 6:14 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- RA Capital Healthcare Fund LP ↗
Director · 10% owner
CIK 0001315082
- RA CAPITAL MANAGEMENT, L.P. ↗
Director · 10% owner
CIK 0001346824
- Kolchinsky Peter ↗
Director · 10% owner
CIK 0001384859
- Shah Rajeev M. ↗
Director · 10% owner
CIK 0001619841
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- This purchase was made for the purpose of extending the period during which acquisitions can be made pursuant to RA Capital Healthcare Fund, L.P.'s filing under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (as amended).
- F2
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.685 to $6.695 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F3
- RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
- F4
- Held directly by the Fund.
- F5
- Represents previously reported restricted stock unit awards grant to Dr. Kolchinsky.
- F6
- Dr. Kolchinsky is a Managing Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Kolchinsky's arrangement with the Adviser, Dr. Kolchinsky holds the RSUs for the benefit of the Fund. Dr. Kolchinsky is obligated to turn over to the Adviser any net cash or shares received upon settlement of the RSUs, which will offset advisory fees owed by the Fund to the Adviser.
Remarks
Dr. Peter Kolchinsky, a Managing Partner of the Adviser, serves on the Issuer's board of directors.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.